101 related articles for article (PubMed ID: 37440313)
1. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function.
Kumaraswamy A; Duan Z; Flores D; Zhang C; Sehrawat A; Hu YM; Swaim OA; Rodansky E; Storck WK; Kuleape JA; Bedi K; Mannan R; Wang XM; Udager A; Ravikumar V; Bankhead A; Coleman I; Lee JK; Morrissey C; Nelson PS; Chinnaiyan AM; Rao A; Xia Z; Yates JA; Alumkal JJ
JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37440313
[TBL] [Abstract][Full Text] [Related]
2. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
Jasmine S; Mandl A; Krueger TEG; Dalrymple SL; Antony L; Dias J; Celatka CA; Tapper AE; Kleppe M; Kanayama M; Jing Y; Speranzini V; Wang YZ; Luo J; Trock BJ; Denmeade SR; Carducci MA; Mattevi A; Rienhoff HY; Isaacs JT; Nathaniel Brennen W
Prostate; 2024 Apr; ():. PubMed ID: 38619005
[TBL] [Abstract][Full Text] [Related]
3. E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.
Tang F; Lu C; He X; Lin W; Xie B; Gao X; Peng Y; Yang D; Sun L; Weng L
Cell Rep; 2023 Dec; 42(12):113477. PubMed ID: 37979167
[TBL] [Abstract][Full Text] [Related]
4. Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
Liu C; Chen B; Xu P; Yang J; Nip C; Wang L; Shen Y; Ning S; Shang Y; Corey E; Gao AC; Gestwicki J; Wei Q; Liu L
Res Sq; 2024 Mar; ():. PubMed ID: 38585965
[TBL] [Abstract][Full Text] [Related]
5. Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion.
Pallavi R; Gatti E; Durfort T; Stendardo M; Ravasio R; Leonardi T; Falvo P; Duso BA; Punzi S; Xieraili A; Polazzi A; Verrelli D; Trastulli D; Ronzoni S; Frascolla S; Perticari G; Elgendy M; Varasi M; Colombo E; Giorgio M; Lanfrancone L; Minucci S; Mazzarella L; Pelicci PG
Nat Commun; 2024 Jan; 15(1):828. PubMed ID: 38280853
[TBL] [Abstract][Full Text] [Related]
6. Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer.
Wang D; Du G; Chen X; Wang J; Liu K; Zhao H; Cheng C; He Y; Jing N; Xu P; Bao W; Xi X; Zhang Y; Wang N; Liu Y; Sun Y; Zhang K; Zhang P; Gao WQ; Zhu HH
Cell Death Differ; 2024 Apr; ():. PubMed ID: 38654072
[TBL] [Abstract][Full Text] [Related]
7. A hyperthermic seizure unleashes a surge of spreading depolarizations in Scn1a-deficient mice.
Aiba I; Ning Y; Noebels JL
JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37551713
[TBL] [Abstract][Full Text] [Related]
8. A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia.
Tezze C; Amendolagine FI; Nogara L; Baraldo M; Ciciliot S; Arcidiacono D; Zaramella A; Masiero G; Ferrarese G; Realdon S; Blaauw B; Detienne G; Beliën AT; Sandri M; Mercken EM
JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37551712
[TBL] [Abstract][Full Text] [Related]
9. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
10. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.
Li JJ; Vasciaveo A; Karagiannis D; Sun Z; Chen X; Socciarelli F; Frankenstein Z; Zou M; Pannellini T; Chen Y; Gardner K; Robinson BD; de Bono J; Abate-Shen C; Rubin MA; Loda M; Sawyers CL; Califano A; Lu C; Shen MM
bioRxiv; 2023 Jul; ():. PubMed ID: 37502956
[TBL] [Abstract][Full Text] [Related]
11. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.
Yin L; Ye Y; Zou L; Lin J; Dai Y; Fu Y; Liu Y; Peng Y; Gao Y; Fu Y; Qi X; Deng T; Zhang S; Li X
J Exp Clin Cancer Res; 2023 Aug; 42(1):204. PubMed ID: 37563661
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
Soukup J; Manethova M; Stejskal V; Hornychova H; Cesak T; Netuka D; Ryska A; Gabalec F
Endocr Pathol; 2023 Sep; 34(3):333-341. PubMed ID: 37552455
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Chowdhury S; Kennedy JJ; Ivey RG; Murillo OD; Hosseini N; Song X; Petralia F; Calinawan A; Savage SR; Berry AB; Reva B; Ozbek U; Krek A; Ma W; da Veiga Leprevost F; Ji J; Yoo S; Lin C; Voytovich UJ; Huang Y; Lee SH; Bergan L; Lorentzen TD; Mesri M; Rodriguez H; Hoofnagle AN; Herbert ZT; Nesvizhskii AI; Zhang B; Whiteaker JR; Fenyo D; McKerrow W; Wang J; Schürer SC; Stathias V; Chen XS; Barcellos-Hoff MH; Starr TK; Winterhoff BJ; Nelson AC; Mok SC; Kaufmann SH; Drescher C; Cieslik M; Wang P; Birrer MJ; Paulovich AG
Cell; 2023 Aug; 186(16):3476-3498.e35. PubMed ID: 37541199
[TBL] [Abstract][Full Text] [Related]
14. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract][Full Text] [Related]
15. LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy.
Mamun MAA; Zhang Y; Zhao JY; Shen DD; Guo T; Zheng YC; Zhao LJ; Liu HM
J Biomed Sci; 2023 Jul; 30(1):60. PubMed ID: 37525190
[TBL] [Abstract][Full Text] [Related]
16. LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.
Yin Z; Liu S; Yang X; Chen M; Du J; Liu H; Yang L
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513188
[TBL] [Abstract][Full Text] [Related]
17. Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential.
Bao L; Zhu P; Mou Y; Song Y; Qin Y
Front Immunol; 2023; 14():1214675. PubMed ID: 37483603
[TBL] [Abstract][Full Text] [Related]
18. Targeting TRIM24 promotes neuroblastoma differentiation and decreases tumorigenicity via LSD1/CoREST complex.
Shi Q; Yu B; Zhang Y; Yang Y; Xu C; Zhang M; Chen G; Luo F; Sun B; Yang R; Li Y; Feng H
Cell Oncol (Dordr); 2023 Dec; 46(6):1763-1775. PubMed ID: 37466744
[TBL] [Abstract][Full Text] [Related]
19. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.
Tao L; Zhou Y; Pan X; Luo Y; Qiu J; Zhou X; Chen Z; Li Y; Xu L; Zhou Y; Zuo Z; Liu C; Wang L; Liu X; Tian X; Su N; Yang Z; Zhang Y; Gou K; Sang N; Liu H; Zou J; Xiao Y; Zhong X; Xu J; Yang X; Xiao K; Liu Y; Yang S; Peng Y; Han J; Cen X; Zhao Y
Nat Commun; 2023 Nov; 14(1):7430. PubMed ID: 37973845
[TBL] [Abstract][Full Text] [Related]
20. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I; Freeman MR; Encío IJ; Rotinen M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
